{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import re\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "from datetime import datetime\n",
    "from collections import defaultdict\n",
    "from sklearn.metrics import confusion_matrix, ConfusionMatrixDisplay\n",
    "\n",
    "# Import functions from qualitative_analysis\n",
    "from qualitative_analysis.data_processing import load_data, clean_and_normalize, sanitize_dataframe\n",
    "from qualitative_analysis.model_interaction import get_llm_client\n",
    "from qualitative_analysis.evaluation import compute_cohens_kappa\n",
    "from qualitative_analysis.utils import save_results_to_csv, load_results_from_csv\n",
    "import qualitative_analysis.config as config\n",
    "from qualitative_analysis.prompt_construction import construct_prompt\n",
    "from qualitative_analysis.prompt_construction import build_data_format_description\n",
    "from qualitative_analysis.response_parsing import extract_code_from_response\n",
    "from qualitative_analysis.cost_estimation import openai_api_calculate_cost\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define data directory\n",
    "data_dir = 'data'\n",
    "os.makedirs(data_dir, exist_ok=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>title</th>\n",
       "      <th>description</th>\n",
       "      <th>protocol</th>\n",
       "      <th>y_true</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>inhibition of recombinant human full-length hi...</td>\n",
       "      <td>title : discovery of sp-96 , the first non-atp...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>inhibition of human intestinal ces2 expressed ...</td>\n",
       "      <td>title : selective inhibitor of human liver car...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>displacement of eu-dtpa-ndp-a-msh chelate from...</td>\n",
       "      <td>title : synthesis and evaluation of bivalent l...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>binding affinity at mu opioid receptor 1 in ra...</td>\n",
       "      <td>title : synthesis and biological evaluation of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>inhibition of recombinant solanum lycopersicum...</td>\n",
       "      <td>inhibition of recombinant solanum lycopersicum...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-1.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   index                                              title  \\\n",
       "0      0  inhibition of recombinant human full-length hi...   \n",
       "1      1  inhibition of human intestinal ces2 expressed ...   \n",
       "2      2  displacement of eu-dtpa-ndp-a-msh chelate from...   \n",
       "3      3  binding affinity at mu opioid receptor 1 in ra...   \n",
       "4      4  inhibition of recombinant solanum lycopersicum...   \n",
       "\n",
       "                                         description protocol  y_true  \n",
       "0  title : discovery of sp-96 , the first non-atp...      NaN    -1.0  \n",
       "1  title : selective inhibitor of human liver car...      NaN    -1.0  \n",
       "2  title : synthesis and evaluation of bivalent l...      NaN     0.0  \n",
       "3  title : synthesis and biological evaluation of...      NaN     0.0  \n",
       "4  inhibition of recombinant solanum lycopersicum...      NaN    -1.0  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Define the path to your dataset\n",
    "data_file_path = os.path.join(data_dir, 'multiclass_sample.csv')\n",
    "\n",
    "# Load the data\n",
    "data = load_data(data_file_path, file_type='csv', delimiter=';')\n",
    "\n",
    "# Preview the data\n",
    "data.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\ocler\\Documents\\Académique\\Inria\\qualitative_analysis_project\\qualitative_analysis\\data_processing.py:134: FutureWarning: DataFrame.applymap has been deprecated. Use DataFrame.map instead.\n",
      "  return df.applymap(\n"
     ]
    }
   ],
   "source": [
    "# 1) Define a mapping from old column names to new names\n",
    "# rename_map = {\n",
    "#     \"ref\": \"reference\",\n",
    "#     \"txt1.ctrl1\": \"Identify\",\n",
    "#     \"txt1.det\": \"Guess\",\n",
    "#     \"txt1.exp\": \"Seek\",\n",
    "#     \"txt1.ctrl2\": \"Assess\"\n",
    "# }\n",
    "\n",
    "# # 2) Rename the columns in the DataFrame\n",
    "# data = data.rename(columns=rename_map)\n",
    "\n",
    "# 3) Now define the new column names for cleaning\n",
    "text_columns = [\"title\", \"description\"]\n",
    "\n",
    "# 4) Clean and normalize the new columns\n",
    "for col in text_columns:\n",
    "    data[col] = clean_and_normalize(data[col])\n",
    "\n",
    "# 5) Sanitize the DataFrame\n",
    "data = sanitize_dataframe(data)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total number of verbatims: 94\n",
      "Verbatim example:\n",
      "Title: inhibition of recombinant human full-length his-tagged aurora b expressed in baculovirus expression system using 5-fam-lrraslg-conh2 a substrate preincubated for 60 min followed by substrate addition by microfluidic assay\n",
      "\n",
      "Description: title : discovery of sp-96 , the first non-atp-competitive aurora kinase b inhibitor , for reduced myelosuppression . abstract : aurora kinase b is a serine-threonine kinase known to be overexpressed in several cancer , with no inhibitor approved for clinical use . herein , we present the discovery and optimization of a series of novel quinazoline-based aurora kinase b inhibitor . the lead inhibitor sp-96 show sub-nanomolar potency in aurora b enzymatic assay ( ic = 0.316 ± 0.031 nm ) . we identified the important pharmacophore feature resulting in selectivity against receptor tyrosine kinase . particularly , sp-96 show > 2000 fold selectivity against flt3 and kit which is important for normal hematopoiesis . this could diminish the adverse effect of neutropenia reported in the clinical trial of the aurora b inhibitor barasertib , which inhibits flt3 and kit in addition to aurora b. enzyme kinetics of sp-96 show non-atp-competitive inhibition which make it a first-in-class inhibitor . further , sp-96 show selective growth inhibition in nci60 screening , including inhibition of mda-md-468 , a triple negative breast cancer cell line .\n"
     ]
    }
   ],
   "source": [
    "# Combine texts and entries\n",
    "\n",
    "data['verbatim'] = data.apply(\n",
    "    lambda row: (\n",
    "        f\"Title: {row['title']}\\n\\n\"\n",
    "        f\"Description: {row['description']}\"\n",
    "    ),\n",
    "    axis=1\n",
    ")\n",
    "\n",
    "# Extract the list of verbatims\n",
    "verbatims = data['verbatim'].tolist()\n",
    "\n",
    "print(f\"Total number of verbatims: {len(verbatims)}\")\n",
    "print(f\"Verbatim example:\\n{verbatims[0]}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Choose the provider and model\n",
    "provider = 'azure'\n",
    "model_name = 'gpt-4o'\n",
    "\n",
    "# Initialize the client\n",
    "llm_client = get_llm_client(provider=provider, config=config.MODEL_CONFIG[provider])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "=== Processing Verbatim 1/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibition of recombinant human full-length his-tagged aurora b expressed in baculovirus expression system using 5-fam-lrraslg-conh2 a substrate preincubated for 60 min followed by substrate addition by microfluidic assay\n",
      "\n",
      "Description: title : discovery of sp-96 , the first non-atp-competitive aurora kinase b inhibitor , for reduced myelosuppression . abstract : aurora kinase b is a serine-threonine kinase known to be overexpressed in several cancer , with no inhibitor approved for clinical use . herein , we present the discovery and optimization of a series of novel quinazoline-based aurora kinase b inhibitor . the lead inhibitor sp-96 show sub-nanomolar potency in aurora b enzymatic assay ( ic = 0.316 ± 0.031 nm ) . we identified the important pharmacophore feature resulting in selectivity against receptor tyrosine kinase . particularly , sp-96 show > 2000 fold selectivity against flt3 and kit which is important for normal hematopoiesis . this could diminish the adverse effect of neutropenia reported in the clinical trial of the aurora b inhibitor barasertib , which inhibits flt3 and kit in addition to aurora b. enzyme kinetics of sp-96 show non-atp-competitive inhibition which make it a first-in-class inhibitor . further , sp-96 show selective growth inhibition in nci60 screening , including inhibition of mda-md-468 , a triple negative breast cancer cell line .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of a protein. The title mentions \"inhibition of recombinant human full-length his-tagged aurora b,\" and the description further supports this by discussing the discovery of a non-ATP-competitive aurora kinase B inhibitor, SP-96. The description highlights the inhibitor's potency and selectivity, indicating that the bioassay measures the inhibition of aurora kinase B.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is:\n",
      "- -1: inhibition\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of a protein. The title mentions \"inhibition of recombinant human full-length his-tagged aurora b,\" and the description further supports this by discussing the discovery of a non-ATP-competitive aurora kinase B inhibitor, SP-96. The description highlights the inhibitor's potency and selectivity, indicating that the bioassay measures the inhibition of aurora kinase B.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is:\n",
      "- -1: inhibition\n",
      "\n",
      "Tokens Used: 518 (prompt) + 107 (completion) = 625 total\n",
      "Cost for 'Phenotype Classification': $0.0024\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 2/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibition of human intestinal ces2 expressed in baculovirus infected sf9 cell at 10 um using o-nitrophenyl acetate a substrate monitored at 15 sec interval for 5 min relative to control\n",
      "\n",
      "Description: title : selective inhibitor of human liver carboxylesterase based on a β-lapachone scaffold : novel reagent for reaction profiling . abstract : carboxylesterases ( ce ) are ubiquitous enzyme that are responsible for the metabolism of xenobiotics , including drug such a irinotecan and oseltamivir . inhibition of ce significantly modulates the efficacy of such agent . we report here that β-lapachone is a potent , reversible ce inhibitor with ki value in the nanomolar range . a series of amino and phenoxy analogue have been synthesized , and although the former are very poor inhibitor , the latter compound are highly effective in modulating ce activity . our data demonstrate that tautomerism of the amino derivative to the imino form likely account for their loss in biological activity . a series of n-methylated amino derivative , which are unable to undergo such tautomerism , were equal in potency to the phenoxy analogue and demonstrated selectivity for the liver enzyme hce1 . these specific inhibitor , which are active in cell culture model , will be exceptionally useful reagent for reaction profiling of esterified drug in complex biological sample .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of a protein. The title mentions \"inhibition of human intestinal ces2,\" and the description further supports this by discussing the inhibition of carboxylesterases (CE) and the use of β-lapachone as a potent, reversible CE inhibitor. Therefore, the bioassay phenotype should be classified as:\n",
      "\n",
      "-1: inhibition\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of a protein. The title mentions \"inhibition of human intestinal ces2,\" and the description further supports this by discussing the inhibition of carboxylesterases (CE) and the use of β-lapachone as a potent, reversible CE inhibitor. Therefore, the bioassay phenotype should be classified as:\n",
      "\n",
      "-1: inhibition\n",
      "\n",
      "Tokens Used: 482 (prompt) + 83 (completion) = 565 total\n",
      "Cost for 'Phenotype Classification': $0.0020\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 3/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: displacement of eu-dtpa-ndp-a-msh chelate from human melanocortin-4 receptor expressed in hek293 cell after 1 hr by competitive delfia assay\n",
      "\n",
      "Description: title : synthesis and evaluation of bivalent ligand for binding to the human melanocortin-4 receptor . abstract : membrane protein , especially g-protein coupled receptor ( gpcrs ) , are interesting and important theragnostic target since many of them serve in intracellular signaling critical for all aspect of health and disease . the potential utility of designed bivalent ligand a targeting agent for cancer diagnosis and/or therapy can be evaluated by determining their binding to the corresponding receptor . a proof of concept , gpcr cell surface protein are shown to be targeted specifically using multivalent ligand . we designed , synthesized , and tested a series of bivalent ligand targeting the over-expressed human melanocortin 4 receptor ( hmc4r ) in human embryonic kidney ( hek ) 293 cell . based on our data suggesting an optimal linker length of 25±10å inferred from the bivalent melanocyte stimulating hormone ( msh ) agonist , the truncated heptapeptide , referred to a msh ( 7 ) : ac-ser-nle-glu-his-d-phe-arg-trp-nh2 wa used to construct a set of bivalent ligand incorporating a hmc4r antagonist , shu9119 : ac-nle-c [ asp-his-2'-d-nal-arg-trp-lys ] -nh2 and another set of bivalent ligand containing the shu9119 antagonist pharmacophore on both side of the optimized linkers . these two binding motif within the bivalent construct were conjoined by semi-rigid ( pro-gly ) 3 unit with or without the flexible poly ( ethylene glycol ) ( pego ) moiety . lanthanide-based competitive binding assay showed bivalent ligand bind to the hmc4r with up to 240-fold higher affinity than the corresponding linked monovalent ligand .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on the binding affinity of bivalent ligands to the human melanocortin-4 receptor (hMC4R). The description mentions the use of a competitive binding assay to evaluate the binding of these ligands to the receptor. The ligands include an antagonist, SHU9119, which suggests that the assay is measuring the inhibition of the receptor's activity by these ligands.\n",
      "\n",
      "The key points from the description are:\n",
      "- The use of SHU9119, which is known as an antagonist, indicates that the assay is likely measuring inhibition.\n",
      "- The competitive binding assay is used to determine how well these ligands bind to the receptor, which is typically related to inhibition when antagonists are involved.\n",
      "\n",
      "Therefore, the bioassay phenotype can be classified as:\n",
      "-1: inhibition (since the assay measures the inhibition of the human melanocortin-4 receptor by antagonistic ligands).\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on the binding affinity of bivalent ligands to the human melanocortin-4 receptor (hMC4R). The description mentions the use of a competitive binding assay to evaluate the binding of these ligands to the receptor. The ligands include an antagonist, SHU9119, which suggests that the assay is measuring the inhibition of the receptor's activity by these ligands.\n",
      "\n",
      "The key points from the description are:\n",
      "- The use of SHU9119, which is known as an antagonist, indicates that the assay is likely measuring inhibition.\n",
      "- The competitive binding assay is used to determine how well these ligands bind to the receptor, which is typically related to inhibition when antagonists are involved.\n",
      "\n",
      "Therefore, the bioassay phenotype can be classified as:\n",
      "-1: inhibition (since the assay measures the inhibition of the human melanocortin-4 receptor by antagonistic ligands).\n",
      "\n",
      "Tokens Used: 618 (prompt) + 193 (completion) = 811 total\n",
      "Cost for 'Phenotype Classification': $0.0035\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 4/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: binding affinity at mu opioid receptor 1 in rat brain membrane by [ 3h ] damgo displacement .\n",
      "\n",
      "Description: title : synthesis and biological evaluation of 14-alkoxymorphinans . 17. highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans . abstract : 14-alkoxy analogue of naltrindole and naltriben differently substituted in position 5 and 17 and at the indole nitrogen ( compound 28-44 ) have been synthesized in an effort to enhance the delta potency and/or delta selectivity and in order to further elaborate on structure-activity relationship of this class of compound . introduction of a 14-alkoxy instead of the 14-hydroxy group present in naltrindole resulted in somewhat lower delta binding affinity , while in many case ( compound 31 , 34 , 37 , 40 , 41 , 44 , h 378 ) the delta receptor selectivity wa considerably increased . an ethoxy group in position 14 is superior to other alkoxy group concerning delta affinity and selectivity ( 34 , 41 , 42 , 44 , h 378 ) . in [ 35s ] gtp gamma s binding , compound 34 , 41 , and h 378 exhibited about one-tenth the antagonist potency of naltrindole at delta opioid receptor while their delta antagonist selectivity wa considerably higher . 17-methyl-substituted compound 35 and 44 were found to be pure delta receptor agonist in this test .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "To classify the phenotype of the bioassay, we need to determine whether the bioassay measures activation or inhibition of a protein, or if it is unclear.\n",
      "\n",
      "Let's analyze the provided entry:\n",
      "\n",
      "**Title:** \"binding affinity at mu opioid receptor 1 in rat brain membrane by [ 3h ] damgo displacement.\"\n",
      "\n",
      "The title suggests that the bioassay involves measuring binding affinity at the mu opioid receptor, which could imply either activation or inhibition, but it is not specific.\n",
      "\n",
      "**Description:** The description discusses the synthesis and evaluation of 14-alkoxymorphinans, focusing on their selectivity and potency at the delta opioid receptor. It mentions that some compounds exhibited antagonist potency at the delta opioid receptor, which indicates inhibition. Specifically, it states that compounds 34, 41, and H 378 exhibited about one-tenth the antagonist potency of naltrindole at the delta opioid receptor, and that 17-methyl-substituted compounds 35 and 44 were found to be pure delta receptor agonists.\n",
      "\n",
      "The key points from the description are:\n",
      "- The mention of \"antagonist potency\" suggests inhibition at the delta opioid receptor.\n",
      "- The mention of \"pure delta receptor agonists\" suggests activation, but this is specifically for the delta receptor, not the mu opioid receptor mentioned in the title.\n",
      "\n",
      "Since the title refers to the mu opioid receptor and the description provides evidence of antagonist activity (inhibition) at the delta opioid receptor, the bioassay seems to focus on inhibition, particularly given the context of displacement assays which often measure competitive binding (a form of inhibition).\n",
      "\n",
      "Therefore, based on the information provided, the bioassay phenotype is best classified as:\n",
      "\n",
      "**Phenotype Classification: -1 (inhibition)**\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "To classify the phenotype of the bioassay, we need to determine whether the bioassay measures activation or inhibition of a protein, or if it is unclear.\n",
      "\n",
      "Let's analyze the provided entry:\n",
      "\n",
      "**Title:** \"binding affinity at mu opioid receptor 1 in rat brain membrane by [ 3h ] damgo displacement.\"\n",
      "\n",
      "The title suggests that the bioassay involves measuring binding affinity at the mu opioid receptor, which could imply either activation or inhibition, but it is not specific.\n",
      "\n",
      "**Description:** The description discusses the synthesis and evaluation of 14-alkoxymorphinans, focusing on their selectivity and potency at the delta opioid receptor. It mentions that some compounds exhibited antagonist potency at the delta opioid receptor, which indicates inhibition. Specifically, it states that compounds 34, 41, and H 378 exhibited about one-tenth the antagonist potency of naltrindole at the delta opioid receptor, and that 17-methyl-substituted compounds 35 and 44 were found to be pure delta receptor agonists.\n",
      "\n",
      "The key points from the description are:\n",
      "- The mention of \"antagonist potency\" suggests inhibition at the delta opioid receptor.\n",
      "- The mention of \"pure delta receptor agonists\" suggests activation, but this is specifically for the delta receptor, not the mu opioid receptor mentioned in the title.\n",
      "\n",
      "Since the title refers to the mu opioid receptor and the description provides evidence of antagonist activity (inhibition) at the delta opioid receptor, the bioassay seems to focus on inhibition, particularly given the context of displacement assays which often measure competitive binding (a form of inhibition).\n",
      "\n",
      "Therefore, based on the information provided, the bioassay phenotype is best classified as:\n",
      "\n",
      "**Phenotype Classification: -1 (inhibition)**\n",
      "\n",
      "Tokens Used: 529 (prompt) + 352 (completion) = 881 total\n",
      "Cost for 'Phenotype Classification': $0.0048\n",
      "Extracted Label: 1\n",
      "\n",
      "=== Processing Verbatim 5/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibition of recombinant solanum lycopersicum ( tomato ) fatty acid 13-hydroperoxide lyase using ( 13 ) -hpot substrate by spectrophotometry\n",
      "\n",
      "Description: inhibition of recombinant solanum lycopersicum ( tomato ) fatty acid 13-hydroperoxide lyase using ( 13 ) -hpot substrate by spectrophotometry\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, both the title and the description indicate that the bioassay measures the inhibition of a protein. Specifically, it mentions the \"inhibition of recombinant solanum lycopersicum (tomato) fatty acid 13-hydroperoxide lyase.\" Since the bioassay is focused on measuring the inhibition of this enzyme, the appropriate classification for the phenotype is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "Therefore, the bioassay phenotype should be classified as -1.\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, both the title and the description indicate that the bioassay measures the inhibition of a protein. Specifically, it mentions the \"inhibition of recombinant solanum lycopersicum (tomato) fatty acid 13-hydroperoxide lyase.\" Since the bioassay is focused on measuring the inhibition of this enzyme, the appropriate classification for the phenotype is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "Therefore, the bioassay phenotype should be classified as -1.\n",
      "\n",
      "Tokens Used: 282 (prompt) + 99 (completion) = 381 total\n",
      "Cost for 'Phenotype Classification': $0.0017\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 6/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibitory activity against phenylethanolamine n-methyl-transferase\n",
      "\n",
      "Description: title : importance of the aromatic ring in adrenergic amine . 5. nonaromatic analogue of phenylethanolamine a inhibitor of phenylethanolamine n-methyltransferase : role of hydrophobic and steric interaction .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the title \"inhibitory activity against phenylethanolamine n-methyl-transferase\" clearly indicates that the bioassay is measuring the inhibition of a protein, specifically phenylethanolamine n-methyltransferase. The description further supports this by mentioning \"a inhibitor of phenylethanolamine n-methyltransferase,\" which confirms the inhibitory nature of the bioassay.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is:\n",
      "- -1: inhibition\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the title \"inhibitory activity against phenylethanolamine n-methyl-transferase\" clearly indicates that the bioassay is measuring the inhibition of a protein, specifically phenylethanolamine n-methyltransferase. The description further supports this by mentioning \"a inhibitor of phenylethanolamine n-methyltransferase,\" which confirms the inhibitory nature of the bioassay.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is:\n",
      "- -1: inhibition\n",
      "\n",
      "Tokens Used: 272 (prompt) + 102 (completion) = 374 total\n",
      "Cost for 'Phenotype Classification': $0.0017\n",
      "Extracted Label: -1\n",
      "\n",
      "=== Processing Verbatim 7/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: displacement of [ 3h ] win-35428 ( 0.5 nm ) from dopamine transporter\n",
      "\n",
      "Description: title : synthesis and ligand binding of tropane ring analogue of paroxetine . abstract : ( 3s,4r ) -4- ( 4-fluorophenyl ) -3- [ [ 3,4- ( methylenedioxy ) phenoxy ] methyl ] piperidine [ ( 3s,9r ) -3 , paroxetine ] is a selective serotonin reuptake inhibitor ( ssri ) used a an antidepressant in human . in previous study , we reported that certain ( 1r ) -3 beta- ( substituted phenyl ) nortropane-2 beta-carboxylic acid methyl ester ( 2a ) exhibited high affinity and reasonable selectivity for the serotonin transporter ( 5-htt ) . the major structural difference between 2a and ( 3s,4r ) -3 are that 2a posse a different absolute stereochemistry and ha an ethylene bridge not present in 3. in addition , 2a posse a carbomethoxy substituent adjacent to the aryl ring , whereas ( 3s,4r ) -3 contains a [ 3,4- ( methylenedioxy ) phenoxy ] methyl group . in this study , we present the synthesis and biological evaluation of six of the possible eight isomer of 3- ( 4-fluorophenyl ) -2- [ [ 3,4- ( methylenedioxy ) phenoxy ] methyl ] nortropane+ ++ ( 4 ) . the data for inhibition of [ 3h ] paroxetine binding show that ( 1r ) -2 beta , 3 alpha-4c , which ha the same stereochemistry a paroxetine , ha the highest affinity at the 5-htt . strikingly , the most potent compound for inhibition of [ 3h ] win-35,428 binding were not the ( 1r ) -2 beta , 3 beta-isomers but rather ( 1r ) -2 beta , 3 alpha-4c and ( 1 ) -2 beta , 3 alpha-4f . conformational analysis show that these isomer exist in a flattened boat conformation with pseudoequatorial substituents . thus , the binding data show that this conformation is recognized by the dat-associated binding site and also suggest that this conformation of paroxetine is recognized by the 5-htt-associated binding site .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on measuring the binding affinity of compounds to the dopamine transporter (DAT) and serotonin transporter (5-HTT). The description specifically mentions \"inhibition of [ 3h ] paroxetine binding\" and \"the most potent compound for inhibition of [ 3h ] win-35,428 binding.\" This indicates that the bioassay is measuring the inhibition of binding to these transporters.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is:\n",
      "\n",
      "- -1: inhibition (since the bioassay measures the inhibition of binding to the dopamine transporter and serotonin transporter).\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on measuring the binding affinity of compounds to the dopamine transporter (DAT) and serotonin transporter (5-HTT). The description specifically mentions \"inhibition of [ 3h ] paroxetine binding\" and \"the most potent compound for inhibition of [ 3h ] win-35,428 binding.\" This indicates that the bioassay is measuring the inhibition of binding to these transporters.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is:\n",
      "\n",
      "- -1: inhibition (since the bioassay measures the inhibition of binding to the dopamine transporter and serotonin transporter).\n",
      "\n",
      "Tokens Used: 731 (prompt) + 127 (completion) = 858 total\n",
      "Cost for 'Phenotype Classification': $0.0031\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 8/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: antagonist activity at prolink-tagged human cxcr6 receptor assessed a inhibition of cxcl16-induced beta-arrestin recruitment by discoverx cell based assay relative to control\n",
      "\n",
      "Description: title : discovery of small molecule antagonist of chemokine receptor cxcr6 that arrest tumor growth in sk-hep-1 mouse xenograft a a model of hepatocellular carcinoma . abstract : the chemokine system play an important role in mediating a proinflammatory microenvironment for tumor growth in hepatocellular carcinoma ( hcc ) . the cxcr6 receptor and it natural ligand cxcl16 are expressed at high level in hcc cell line and tumor tissue and receptor expression correlate with increased neutrophil in these tissue contributing to poor prognosis in patient . availability of pharmacologcal tool targeting the cxcr6/cxcl16 axis are needed to elucidate the mechanism whereby neutrophil are affected in the tumor environment . we report the discovery of a series of small molecule with an exo- [ 3.3.1 ] azabicyclononane core . our lead compound 81 is a potent ( ec < sub > 50 < /sub > = 40 nm ) and selective orally bioavailable small molecule antagonist of human cxcr6 receptor signaling that significantly decrease tumor growth in a 30-day mouse xenograft model of hcc .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "To classify the bioassay phenotype, we need to determine whether the bioassay measures activation or inhibition of a protein. Let's analyze the provided entry:\n",
      "\n",
      "**Title:**\n",
      "\"antagonist activity at prolink-tagged human cxcr6 receptor assessed a inhibition of cxcl16-induced beta-arrestin recruitment by discoverx cell based assay relative to control\"\n",
      "\n",
      "The title mentions \"antagonist activity\" and \"inhibition of cxcl16-induced beta-arrestin recruitment,\" which suggests that the bioassay is measuring inhibition.\n",
      "\n",
      "**Description:**\n",
      "The description provides additional context:\n",
      "- It discusses the discovery of a small molecule antagonist of the chemokine receptor CXCR6.\n",
      "- The lead compound is described as a \"potent and selective orally bioavailable small molecule antagonist of human cxcr6 receptor signaling.\"\n",
      "- The compound \"significantly decrease[s] tumor growth\" in a mouse model.\n",
      "\n",
      "The description reinforces that the bioassay is focused on the inhibition of the CXCR6 receptor signaling, as it involves an antagonist that inhibits the receptor's activity.\n",
      "\n",
      "Based on both the title and the description, the bioassay is clearly measuring the inhibition of the CXCR6 receptor. Therefore, the appropriate phenotype classification for this bioassay is:\n",
      "\n",
      "- **-1: inhibition**\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "To classify the bioassay phenotype, we need to determine whether the bioassay measures activation or inhibition of a protein. Let's analyze the provided entry:\n",
      "\n",
      "**Title:**\n",
      "\"antagonist activity at prolink-tagged human cxcr6 receptor assessed a inhibition of cxcl16-induced beta-arrestin recruitment by discoverx cell based assay relative to control\"\n",
      "\n",
      "The title mentions \"antagonist activity\" and \"inhibition of cxcl16-induced beta-arrestin recruitment,\" which suggests that the bioassay is measuring inhibition.\n",
      "\n",
      "**Description:**\n",
      "The description provides additional context:\n",
      "- It discusses the discovery of a small molecule antagonist of the chemokine receptor CXCR6.\n",
      "- The lead compound is described as a \"potent and selective orally bioavailable small molecule antagonist of human cxcr6 receptor signaling.\"\n",
      "- The compound \"significantly decrease[s] tumor growth\" in a mouse model.\n",
      "\n",
      "The description reinforces that the bioassay is focused on the inhibition of the CXCR6 receptor signaling, as it involves an antagonist that inhibits the receptor's activity.\n",
      "\n",
      "Based on both the title and the description, the bioassay is clearly measuring the inhibition of the CXCR6 receptor. Therefore, the appropriate phenotype classification for this bioassay is:\n",
      "\n",
      "- **-1: inhibition**\n",
      "\n",
      "Tokens Used: 482 (prompt) + 261 (completion) = 743 total\n",
      "Cost for 'Phenotype Classification': $0.0038\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 9/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: average binding constant for map3k4 . na=not active at 10 um\n",
      "\n",
      "Description: title : a small molecule-kinase interaction map for clinical kinase inhibitor . abstract : kinase inhibitor show great promise a a new class of therapeutic . here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecule to the atp site of kinase . we have profiled 20 kinase inhibitor , including 16 that are approved drug or in clinical development , against a panel of 119 protein kinase . we find that specificity varies widely and is not strongly correlated with chemical structure or the identity of the intended target . many novel interaction were identified , including tight binding of the p38 inhibitor birb-796 to an imatinib-resistant variant of the abl kinase , and binding of imatinib to the src-family kinase lck . we also show that mutation in the epidermal growth factor receptor ( egfr ) found in gefitinib-responsive patient do not affect the binding affinity of gefitinib or erlotinib . our result represent a systematic small molecule-protein interaction map for clinical compound across a large number of related protein .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, we need to determine the phenotype classification of the bioassay.\n",
      "\n",
      "**Title:** \"average binding constant for map3k4 . na=not active at 10 um\"\n",
      "\n",
      "**Description:** The description discusses a study on kinase inhibitors, which are compounds that typically inhibit the activity of kinases by binding to their ATP sites. The description mentions profiling kinase inhibitors against a panel of protein kinases and highlights specific interactions, such as the binding of inhibitors to certain kinases. The focus is on measuring the binding of small molecules to kinases, which suggests inhibition rather than activation, as kinase inhibitors are generally designed to block kinase activity.\n",
      "\n",
      "Given that the bioassay involves measuring the binding of kinase inhibitors to kinases, it is reasonable to classify this as measuring inhibition.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is **-1: inhibition**.\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, we need to determine the phenotype classification of the bioassay.\n",
      "\n",
      "**Title:** \"average binding constant for map3k4 . na=not active at 10 um\"\n",
      "\n",
      "**Description:** The description discusses a study on kinase inhibitors, which are compounds that typically inhibit the activity of kinases by binding to their ATP sites. The description mentions profiling kinase inhibitors against a panel of protein kinases and highlights specific interactions, such as the binding of inhibitors to certain kinases. The focus is on measuring the binding of small molecules to kinases, which suggests inhibition rather than activation, as kinase inhibitors are generally designed to block kinase activity.\n",
      "\n",
      "Given that the bioassay involves measuring the binding of kinase inhibitors to kinases, it is reasonable to classify this as measuring inhibition.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is **-1: inhibition**.\n",
      "\n",
      "Tokens Used: 437 (prompt) + 177 (completion) = 614 total\n",
      "Cost for 'Phenotype Classification': $0.0029\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 10/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: binding affinity to naaladase\n",
      "\n",
      "Description: title : radiofluorinated derivative of 2- ( phosphonomethyl ) pentanedioic acid a inhibitor of prostate specific membrane antigen ( psma ) for the imaging of prostate cancer . abstract : for prostate cancer , prostate specific membrane antigen ( psma ) ha been identified a a diagnostic and therapeutic target . fluorinated derivative of 2- ( phosphonomethyl ) pentanedioic acid were designed and synthesized to explore whether this fluorine-substituent is tolerated in the pentanedioic acid moiety that is common to almost all psma targeting small molecule inhibitor . the binding affinity of the racemic and individual stereoisomers of 2-fluoro-4- ( phosphonomethyl ) pentanedioic acid were determined and showed that the introduction of fluorine wa well tolerated . the radiosynthesis of the analogous 2- [ ( 18 ) f ] fluoro-4- ( phosphonomethyl ) pentanedioic acid wa developed and evaluated in vivo with the psma positive lncap human prostate cancer cell . the biological result demonstrated specific binding of the tracer to psma positive tumor in mouse . these result warrant the further evaluation of this class of compound a radiolabeled tracer for the detection and staging of prostate cancer .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on the binding affinity of a compound to naaladase, which is related to prostate-specific membrane antigen (PSMA). The description mentions that the compound is an inhibitor of PSMA, which is a protein. Therefore, the bioassay measures the inhibition of a protein.\n",
      "\n",
      "Given this information, the appropriate classification for the bioassay phenotype is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on the binding affinity of a compound to naaladase, which is related to prostate-specific membrane antigen (PSMA). The description mentions that the compound is an inhibitor of PSMA, which is a protein. Therefore, the bioassay measures the inhibition of a protein.\n",
      "\n",
      "Given this information, the appropriate classification for the bioassay phenotype is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "Tokens Used: 468 (prompt) + 87 (completion) = 555 total\n",
      "Cost for 'Phenotype Classification': $0.0020\n",
      "Extracted Label: -1\n",
      "\n",
      "=== Processing Verbatim 11/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: induction of egfr covalent modification assessed a alkylation after 3 hr by lc/ms mass spectroscopy\n",
      "\n",
      "Description: title : synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual egfr/erbb-2 kinase inhibitor . abstract : aniline 'headgroups ' were synthesized and incorporated into an alkynyl thienopyrimidine series of egfr and erbb-2 inhibitor . potent inhibition of enzyme activity and cellular proliferation wa observed . in certain instance , protein binding wa reduced and oral exposure wa found to be somewhat improved relative to compound containing the reference aniline .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, we need to determine the phenotype classification of the bioassay.\n",
      "\n",
      "The title mentions \"induction of egfr covalent modification,\" which suggests some form of modification or interaction with the EGFR protein. However, it does not clearly specify whether this is activation or inhibition.\n",
      "\n",
      "The description provides more context: it discusses the synthesis and evaluation of compounds as \"dual egfr/erbb-2 kinase inhibitors.\" It specifically mentions \"potent inhibition of enzyme activity and cellular proliferation,\" which indicates that the bioassay is measuring the inhibition of the EGFR and ERBB-2 kinases.\n",
      "\n",
      "Given this information, the bioassay is focused on measuring the inhibition of protein activity. Therefore, the appropriate phenotype classification for this bioassay is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "This classification is based on the description's emphasis on the inhibitory effects of the compounds on enzyme activity.\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, we need to determine the phenotype classification of the bioassay.\n",
      "\n",
      "The title mentions \"induction of egfr covalent modification,\" which suggests some form of modification or interaction with the EGFR protein. However, it does not clearly specify whether this is activation or inhibition.\n",
      "\n",
      "The description provides more context: it discusses the synthesis and evaluation of compounds as \"dual egfr/erbb-2 kinase inhibitors.\" It specifically mentions \"potent inhibition of enzyme activity and cellular proliferation,\" which indicates that the bioassay is measuring the inhibition of the EGFR and ERBB-2 kinases.\n",
      "\n",
      "Given this information, the bioassay is focused on measuring the inhibition of protein activity. Therefore, the appropriate phenotype classification for this bioassay is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "This classification is based on the description's emphasis on the inhibitory effects of the compounds on enzyme activity.\n",
      "\n",
      "Tokens Used: 330 (prompt) + 181 (completion) = 511 total\n",
      "Cost for 'Phenotype Classification': $0.0026\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 12/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibition of lsd1 in human thp1 cell assessed a increase in cd86 expression incubated for 48 hr by flow cytometric analysis\n",
      "\n",
      "Description: title : discovery of reversible inhibitor of kdm1a efficacious in acute myeloid leukemia model . abstract : lysine-specific demethylase 1 ( lsd1 or kdm1a ) is a fad-dependent enzyme that act a a transcription corepressor or coactivator by regulating the methylation status of histone h3 lysine k4 and k9 , respectively . kdm1a represents an attractive target for cancer therapy . while , in the past , the main medicinal chemistry strategy toward kdm1a inhibition wa based on the optimization of ligand that irreversibly bind the fad cofactor within the enzyme catalytic site , we and others have also identified reversible inhibitor . herein we reported the discovery of 5-imidazolylthieno [ 3,2- < i > b < /i > ] pyrroles , a new series of kdm1a inhibitor endowed with picomolar inhibitory potency , active in cell and efficacious after oral administration in murine leukemia model .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "To classify the phenotype of the bioassay, we need to determine whether the bioassay measures the activation or inhibition of a protein.\n",
      "\n",
      "1. **Title Analysis:**\n",
      "   - The title mentions \"inhibition of lsd1 in human thp1 cell,\" which suggests that the bioassay is measuring the inhibition of the LSD1 protein.\n",
      "\n",
      "2. **Description Analysis:**\n",
      "   - The description provides further context, stating that LSD1 (also known as KDM1A) is a target for inhibition. It mentions the discovery of reversible inhibitors of KDM1A, which are active in cells and effective in a leukemia model.\n",
      "   - The description emphasizes the development of inhibitors for KDM1A, reinforcing the idea that the bioassay is focused on inhibition.\n",
      "\n",
      "Based on both the title and the description, it is clear that the bioassay is measuring the inhibition of the LSD1 (KDM1A) protein.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is **-1: inhibition**.\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "To classify the phenotype of the bioassay, we need to determine whether the bioassay measures the activation or inhibition of a protein.\n",
      "\n",
      "1. **Title Analysis:**\n",
      "   - The title mentions \"inhibition of lsd1 in human thp1 cell,\" which suggests that the bioassay is measuring the inhibition of the LSD1 protein.\n",
      "\n",
      "2. **Description Analysis:**\n",
      "   - The description provides further context, stating that LSD1 (also known as KDM1A) is a target for inhibition. It mentions the discovery of reversible inhibitors of KDM1A, which are active in cells and effective in a leukemia model.\n",
      "   - The description emphasizes the development of inhibitors for KDM1A, reinforcing the idea that the bioassay is focused on inhibition.\n",
      "\n",
      "Based on both the title and the description, it is clear that the bioassay is measuring the inhibition of the LSD1 (KDM1A) protein.\n",
      "\n",
      "Therefore, the phenotype classification for this bioassay is **-1: inhibition**.\n",
      "\n",
      "Tokens Used: 440 (prompt) + 209 (completion) = 649 total\n",
      "Cost for 'Phenotype Classification': $0.0032\n",
      "Extracted Label: 1\n",
      "\n",
      "=== Processing Verbatim 13/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibition of human recombinant faah using [ 3h ] anandamide by competitive hydrolysis assay\n",
      "\n",
      "Description: title : beta-lactams derived from a carbapenem chiron are selective inhibitor of human fatty acid amide hydrolase versus human monoacylglycerol lipase . abstract : a library of 30 beta-lactams ha been prepared from ( 3r,4r ) -3- [ ( r ) -1'- ( tbutyldimethylsilyloxy ) -ethyl ] -4-acetoxy-2-azetidinone , and the corresponding deacetoxy derivative , by sequential n- and o-functionalizations with various omega-alkenoyl and omega-arylalkanoyl chain . all compound were selective inhibitor of hfaah versus hmgl , and ic ( 50 ) value in the nanomolar range ( 5-14 nm ) were recorded for the best representative . from time-dependent preincubation and rapid dilution study , and from docking analysis in a homology model of the target enzyme , a reversible mechanism of inhibition of hfaah is proposed .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of a protein. The title explicitly mentions \"inhibition of human recombinant faah,\" and the description further supports this by discussing \"selective inhibitor of human fatty acid amide hydrolase\" and \"a reversible mechanism of inhibition of hfaah is proposed.\"\n",
      "\n",
      "Therefore, the bioassay phenotype should be classified as:\n",
      "- -1: inhibition\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of a protein. The title explicitly mentions \"inhibition of human recombinant faah,\" and the description further supports this by discussing \"selective inhibitor of human fatty acid amide hydrolase\" and \"a reversible mechanism of inhibition of hfaah is proposed.\"\n",
      "\n",
      "Therefore, the bioassay phenotype should be classified as:\n",
      "- -1: inhibition\n",
      "\n",
      "Tokens Used: 438 (prompt) + 85 (completion) = 523 total\n",
      "Cost for 'Phenotype Classification': $0.0019\n",
      "Extracted Label: -1\n",
      "\n",
      "=== Processing Verbatim 14/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibition of [ 3h ] pcck-8 binding to cholecystokinin type a receptor of rat pancreas\n",
      "\n",
      "Description: title : 5- ( tryptophyl ) amino-1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine-based potent and selective cck ( 1 ) receptor antagonist : structure-activity relationship study on the central 1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine scaffold . abstract : to further define the pharmacophore of the potent and selective 5- ( tryptophyl ) amino-1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine-based cck ( 1 ) receptor antagonist the electronic and topographic property of the central 1,3-dioxoperhydro-pyrido [ 1,2-c ] pyrimidine scaffold have been modified . with this aim , the 1- and 3-oxo group have been replaced by the thioxo- and deoxi-analogues , and the fused piperidine ring ha been contracted to the corresponding pyrrolidine moiety . the result of the evaluation of the new analogue a cck receptor ligand , in rat pancreas and cerebral cortex preparation , showed that , whereas replacement of oxygen with sulfur is allowed , reduction of the 1- or 3-oxo group or the contraction of the fused piperidine ring lead to the complete loss of binding affinity at cck ( 1 ) receptor . the thioxo-analogues 5a , 8a , 12a , and 12b showed functional cck ( 1 ) antagonist activity , inhibiting the cck-8-stimulated amylase release from pancreatic acinar cell . the 1-thioxo analogue 5a , with subnanomolar affinity ( ic ( 50 ) = 0.09 x 10 ( -9 ) m ) , wa found to be the most potent and selective compound within the family of 5- ( tryptophyl ) amino-1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine-based cck ( 1 ) antagonist .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of binding to the cholecystokinin type A receptor. The title explicitly mentions \"inhibition of [3h] pcck-8 binding to cholecystokinin type a receptor of rat pancreas.\" Additionally, the description supports this by discussing the activity of compounds as \"cck (1) antagonist,\" which implies inhibition of the receptor's activity.\n",
      "\n",
      "Therefore, the bioassay phenotype should be classified as:\n",
      "- -1: inhibition (since the bioassay measures the inhibition of a protein).\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on the inhibition of binding to the cholecystokinin type A receptor. The title explicitly mentions \"inhibition of [3h] pcck-8 binding to cholecystokinin type a receptor of rat pancreas.\" Additionally, the description supports this by discussing the activity of compounds as \"cck (1) antagonist,\" which implies inhibition of the receptor's activity.\n",
      "\n",
      "Therefore, the bioassay phenotype should be classified as:\n",
      "- -1: inhibition (since the bioassay measures the inhibition of a protein).\n",
      "\n",
      "Tokens Used: 671 (prompt) + 121 (completion) = 792 total\n",
      "Cost for 'Phenotype Classification': $0.0029\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Verbatim 15/15 ===\n",
      "\n",
      "--- Evaluating Theme: Phenotype Classification ---\n",
      "=== Single-step Classification Prompt ===\n",
      "Prompt:\n",
      "You are a helpful assistant tasked with evaluating the following entry.\n",
      "\n",
      "You are provided with data entries in the following format:\n",
      "\n",
      "The data has the following columns:\n",
      "- \"Title\": the title of the bioassay\n",
      "- \"Description\": the description of the bioassay\n",
      "\n",
      "\n",
      "**Entry:**\n",
      "Title: inhibition of hdac6 ( unknown origin )\n",
      "\n",
      "Description: title : development of a selective hdac inhibitor aimed at reactivating the hiv latent reservoir . abstract : the synthesis and sar development of a trisubstituted imidazole hdac inhibitor is described . the compound were synthesized with high diastereocontrol by leveraging ellman sulfinyl imine chemistry . structural elucidation provided insight into binding mode and supported design rational . pharmacokinetic property of lead compound were determined .\n",
      "\n",
      "**Task:**\n",
      "Phenotype Classification - \n",
      "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
      "You must classify the bioassay phenotype into one of the following categories:\n",
      "- 1: activation (if the bioassay measures the activation of a protein),\n",
      "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
      "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
      "\n",
      "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
      "\n",
      "Generation:\n",
      "Based on the provided entry, the bioassay is focused on the \"inhibition of hdac6.\" The description further supports this by discussing the development of a selective HDAC inhibitor. The term \"inhibitor\" clearly indicates that the bioassay measures the inhibition of a protein, specifically HDAC6.\n",
      "\n",
      "Therefore, the appropriate classification for the bioassay phenotype is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "\n",
      "=== LLM Response (Single-step Classification) ===\n",
      "Based on the provided entry, the bioassay is focused on the \"inhibition of hdac6.\" The description further supports this by discussing the development of a selective HDAC inhibitor. The term \"inhibitor\" clearly indicates that the bioassay measures the inhibition of a protein, specifically HDAC6.\n",
      "\n",
      "Therefore, the appropriate classification for the bioassay phenotype is:\n",
      "\n",
      "- -1: inhibition\n",
      "\n",
      "Tokens Used: 303 (prompt) + 82 (completion) = 385 total\n",
      "Cost for 'Phenotype Classification': $0.0016\n",
      "Failed to parse a valid label.\n",
      "\n",
      "=== Processing Complete ===\n",
      "Total Tokens Used: 9267\n",
      "Total Cost for Processing: $0.0402\n",
      "{'Verbatim': 'Title: inhibition of recombinant human full-length his-tagged aurora b expressed in baculovirus expression system using 5-fam-lrraslg-conh2 a substrate preincubated for 60 min followed by substrate addition by microfluidic assay\\n\\nDescription: title : discovery of sp-96 , the first non-atp-competitive aurora kinase b inhibitor , for reduced myelosuppression . abstract : aurora kinase b is a serine-threonine kinase known to be overexpressed in several cancer , with no inhibitor approved for clinical use . herein , we present the discovery and optimization of a series of novel quinazoline-based aurora kinase b inhibitor . the lead inhibitor sp-96 show sub-nanomolar potency in aurora b enzymatic assay ( ic = 0.316 ± 0.031 nm ) . we identified the important pharmacophore feature resulting in selectivity against receptor tyrosine kinase . particularly , sp-96 show > 2000 fold selectivity against flt3 and kit which is important for normal hematopoiesis . this could diminish the adverse effect of neutropenia reported in the clinical trial of the aurora b inhibitor barasertib , which inhibits flt3 and kit in addition to aurora b. enzyme kinetics of sp-96 show non-atp-competitive inhibition which make it a first-in-class inhibitor . further , sp-96 show selective growth inhibition in nci60 screening , including inhibition of mda-md-468 , a triple negative breast cancer cell line .', 'Label': None}\n",
      "{'Verbatim': 'Title: inhibition of human intestinal ces2 expressed in baculovirus infected sf9 cell at 10 um using o-nitrophenyl acetate a substrate monitored at 15 sec interval for 5 min relative to control\\n\\nDescription: title : selective inhibitor of human liver carboxylesterase based on a β-lapachone scaffold : novel reagent for reaction profiling . abstract : carboxylesterases ( ce ) are ubiquitous enzyme that are responsible for the metabolism of xenobiotics , including drug such a irinotecan and oseltamivir . inhibition of ce significantly modulates the efficacy of such agent . we report here that β-lapachone is a potent , reversible ce inhibitor with ki value in the nanomolar range . a series of amino and phenoxy analogue have been synthesized , and although the former are very poor inhibitor , the latter compound are highly effective in modulating ce activity . our data demonstrate that tautomerism of the amino derivative to the imino form likely account for their loss in biological activity . a series of n-methylated amino derivative , which are unable to undergo such tautomerism , were equal in potency to the phenoxy analogue and demonstrated selectivity for the liver enzyme hce1 . these specific inhibitor , which are active in cell culture model , will be exceptionally useful reagent for reaction profiling of esterified drug in complex biological sample .', 'Label': None}\n",
      "{'Verbatim': \"Title: displacement of eu-dtpa-ndp-a-msh chelate from human melanocortin-4 receptor expressed in hek293 cell after 1 hr by competitive delfia assay\\n\\nDescription: title : synthesis and evaluation of bivalent ligand for binding to the human melanocortin-4 receptor . abstract : membrane protein , especially g-protein coupled receptor ( gpcrs ) , are interesting and important theragnostic target since many of them serve in intracellular signaling critical for all aspect of health and disease . the potential utility of designed bivalent ligand a targeting agent for cancer diagnosis and/or therapy can be evaluated by determining their binding to the corresponding receptor . a proof of concept , gpcr cell surface protein are shown to be targeted specifically using multivalent ligand . we designed , synthesized , and tested a series of bivalent ligand targeting the over-expressed human melanocortin 4 receptor ( hmc4r ) in human embryonic kidney ( hek ) 293 cell . based on our data suggesting an optimal linker length of 25±10å inferred from the bivalent melanocyte stimulating hormone ( msh ) agonist , the truncated heptapeptide , referred to a msh ( 7 ) : ac-ser-nle-glu-his-d-phe-arg-trp-nh2 wa used to construct a set of bivalent ligand incorporating a hmc4r antagonist , shu9119 : ac-nle-c [ asp-his-2'-d-nal-arg-trp-lys ] -nh2 and another set of bivalent ligand containing the shu9119 antagonist pharmacophore on both side of the optimized linkers . these two binding motif within the bivalent construct were conjoined by semi-rigid ( pro-gly ) 3 unit with or without the flexible poly ( ethylene glycol ) ( pego ) moiety . lanthanide-based competitive binding assay showed bivalent ligand bind to the hmc4r with up to 240-fold higher affinity than the corresponding linked monovalent ligand .\", 'Label': None}\n",
      "{'Verbatim': 'Title: binding affinity at mu opioid receptor 1 in rat brain membrane by [ 3h ] damgo displacement .\\n\\nDescription: title : synthesis and biological evaluation of 14-alkoxymorphinans . 17. highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans . abstract : 14-alkoxy analogue of naltrindole and naltriben differently substituted in position 5 and 17 and at the indole nitrogen ( compound 28-44 ) have been synthesized in an effort to enhance the delta potency and/or delta selectivity and in order to further elaborate on structure-activity relationship of this class of compound . introduction of a 14-alkoxy instead of the 14-hydroxy group present in naltrindole resulted in somewhat lower delta binding affinity , while in many case ( compound 31 , 34 , 37 , 40 , 41 , 44 , h 378 ) the delta receptor selectivity wa considerably increased . an ethoxy group in position 14 is superior to other alkoxy group concerning delta affinity and selectivity ( 34 , 41 , 42 , 44 , h 378 ) . in [ 35s ] gtp gamma s binding , compound 34 , 41 , and h 378 exhibited about one-tenth the antagonist potency of naltrindole at delta opioid receptor while their delta antagonist selectivity wa considerably higher . 17-methyl-substituted compound 35 and 44 were found to be pure delta receptor agonist in this test .', 'Label': 1}\n",
      "{'Verbatim': 'Title: inhibition of recombinant solanum lycopersicum ( tomato ) fatty acid 13-hydroperoxide lyase using ( 13 ) -hpot substrate by spectrophotometry\\n\\nDescription: inhibition of recombinant solanum lycopersicum ( tomato ) fatty acid 13-hydroperoxide lyase using ( 13 ) -hpot substrate by spectrophotometry', 'Label': None}\n",
      "{'Verbatim': 'Title: inhibitory activity against phenylethanolamine n-methyl-transferase\\n\\nDescription: title : importance of the aromatic ring in adrenergic amine . 5. nonaromatic analogue of phenylethanolamine a inhibitor of phenylethanolamine n-methyltransferase : role of hydrophobic and steric interaction .', 'Label': -1}\n",
      "{'Verbatim': 'Title: displacement of [ 3h ] win-35428 ( 0.5 nm ) from dopamine transporter\\n\\nDescription: title : synthesis and ligand binding of tropane ring analogue of paroxetine . abstract : ( 3s,4r ) -4- ( 4-fluorophenyl ) -3- [ [ 3,4- ( methylenedioxy ) phenoxy ] methyl ] piperidine [ ( 3s,9r ) -3 , paroxetine ] is a selective serotonin reuptake inhibitor ( ssri ) used a an antidepressant in human . in previous study , we reported that certain ( 1r ) -3 beta- ( substituted phenyl ) nortropane-2 beta-carboxylic acid methyl ester ( 2a ) exhibited high affinity and reasonable selectivity for the serotonin transporter ( 5-htt ) . the major structural difference between 2a and ( 3s,4r ) -3 are that 2a posse a different absolute stereochemistry and ha an ethylene bridge not present in 3. in addition , 2a posse a carbomethoxy substituent adjacent to the aryl ring , whereas ( 3s,4r ) -3 contains a [ 3,4- ( methylenedioxy ) phenoxy ] methyl group . in this study , we present the synthesis and biological evaluation of six of the possible eight isomer of 3- ( 4-fluorophenyl ) -2- [ [ 3,4- ( methylenedioxy ) phenoxy ] methyl ] nortropane+ ++ ( 4 ) . the data for inhibition of [ 3h ] paroxetine binding show that ( 1r ) -2 beta , 3 alpha-4c , which ha the same stereochemistry a paroxetine , ha the highest affinity at the 5-htt . strikingly , the most potent compound for inhibition of [ 3h ] win-35,428 binding were not the ( 1r ) -2 beta , 3 beta-isomers but rather ( 1r ) -2 beta , 3 alpha-4c and ( 1 ) -2 beta , 3 alpha-4f . conformational analysis show that these isomer exist in a flattened boat conformation with pseudoequatorial substituents . thus , the binding data show that this conformation is recognized by the dat-associated binding site and also suggest that this conformation of paroxetine is recognized by the 5-htt-associated binding site .', 'Label': None}\n",
      "{'Verbatim': 'Title: antagonist activity at prolink-tagged human cxcr6 receptor assessed a inhibition of cxcl16-induced beta-arrestin recruitment by discoverx cell based assay relative to control\\n\\nDescription: title : discovery of small molecule antagonist of chemokine receptor cxcr6 that arrest tumor growth in sk-hep-1 mouse xenograft a a model of hepatocellular carcinoma . abstract : the chemokine system play an important role in mediating a proinflammatory microenvironment for tumor growth in hepatocellular carcinoma ( hcc ) . the cxcr6 receptor and it natural ligand cxcl16 are expressed at high level in hcc cell line and tumor tissue and receptor expression correlate with increased neutrophil in these tissue contributing to poor prognosis in patient . availability of pharmacologcal tool targeting the cxcr6/cxcl16 axis are needed to elucidate the mechanism whereby neutrophil are affected in the tumor environment . we report the discovery of a series of small molecule with an exo- [ 3.3.1 ] azabicyclononane core . our lead compound 81 is a potent ( ec < sub > 50 < /sub > = 40 nm ) and selective orally bioavailable small molecule antagonist of human cxcr6 receptor signaling that significantly decrease tumor growth in a 30-day mouse xenograft model of hcc .', 'Label': None}\n",
      "{'Verbatim': 'Title: average binding constant for map3k4 . na=not active at 10 um\\n\\nDescription: title : a small molecule-kinase interaction map for clinical kinase inhibitor . abstract : kinase inhibitor show great promise a a new class of therapeutic . here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecule to the atp site of kinase . we have profiled 20 kinase inhibitor , including 16 that are approved drug or in clinical development , against a panel of 119 protein kinase . we find that specificity varies widely and is not strongly correlated with chemical structure or the identity of the intended target . many novel interaction were identified , including tight binding of the p38 inhibitor birb-796 to an imatinib-resistant variant of the abl kinase , and binding of imatinib to the src-family kinase lck . we also show that mutation in the epidermal growth factor receptor ( egfr ) found in gefitinib-responsive patient do not affect the binding affinity of gefitinib or erlotinib . our result represent a systematic small molecule-protein interaction map for clinical compound across a large number of related protein .', 'Label': None}\n",
      "{'Verbatim': 'Title: binding affinity to naaladase\\n\\nDescription: title : radiofluorinated derivative of 2- ( phosphonomethyl ) pentanedioic acid a inhibitor of prostate specific membrane antigen ( psma ) for the imaging of prostate cancer . abstract : for prostate cancer , prostate specific membrane antigen ( psma ) ha been identified a a diagnostic and therapeutic target . fluorinated derivative of 2- ( phosphonomethyl ) pentanedioic acid were designed and synthesized to explore whether this fluorine-substituent is tolerated in the pentanedioic acid moiety that is common to almost all psma targeting small molecule inhibitor . the binding affinity of the racemic and individual stereoisomers of 2-fluoro-4- ( phosphonomethyl ) pentanedioic acid were determined and showed that the introduction of fluorine wa well tolerated . the radiosynthesis of the analogous 2- [ ( 18 ) f ] fluoro-4- ( phosphonomethyl ) pentanedioic acid wa developed and evaluated in vivo with the psma positive lncap human prostate cancer cell . the biological result demonstrated specific binding of the tracer to psma positive tumor in mouse . these result warrant the further evaluation of this class of compound a radiolabeled tracer for the detection and staging of prostate cancer .', 'Label': -1}\n",
      "{'Verbatim': \"Title: induction of egfr covalent modification assessed a alkylation after 3 hr by lc/ms mass spectroscopy\\n\\nDescription: title : synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual egfr/erbb-2 kinase inhibitor . abstract : aniline 'headgroups ' were synthesized and incorporated into an alkynyl thienopyrimidine series of egfr and erbb-2 inhibitor . potent inhibition of enzyme activity and cellular proliferation wa observed . in certain instance , protein binding wa reduced and oral exposure wa found to be somewhat improved relative to compound containing the reference aniline .\", 'Label': None}\n",
      "{'Verbatim': 'Title: inhibition of lsd1 in human thp1 cell assessed a increase in cd86 expression incubated for 48 hr by flow cytometric analysis\\n\\nDescription: title : discovery of reversible inhibitor of kdm1a efficacious in acute myeloid leukemia model . abstract : lysine-specific demethylase 1 ( lsd1 or kdm1a ) is a fad-dependent enzyme that act a a transcription corepressor or coactivator by regulating the methylation status of histone h3 lysine k4 and k9 , respectively . kdm1a represents an attractive target for cancer therapy . while , in the past , the main medicinal chemistry strategy toward kdm1a inhibition wa based on the optimization of ligand that irreversibly bind the fad cofactor within the enzyme catalytic site , we and others have also identified reversible inhibitor . herein we reported the discovery of 5-imidazolylthieno [ 3,2- < i > b < /i > ] pyrroles , a new series of kdm1a inhibitor endowed with picomolar inhibitory potency , active in cell and efficacious after oral administration in murine leukemia model .', 'Label': 1}\n",
      "{'Verbatim': \"Title: inhibition of human recombinant faah using [ 3h ] anandamide by competitive hydrolysis assay\\n\\nDescription: title : beta-lactams derived from a carbapenem chiron are selective inhibitor of human fatty acid amide hydrolase versus human monoacylglycerol lipase . abstract : a library of 30 beta-lactams ha been prepared from ( 3r,4r ) -3- [ ( r ) -1'- ( tbutyldimethylsilyloxy ) -ethyl ] -4-acetoxy-2-azetidinone , and the corresponding deacetoxy derivative , by sequential n- and o-functionalizations with various omega-alkenoyl and omega-arylalkanoyl chain . all compound were selective inhibitor of hfaah versus hmgl , and ic ( 50 ) value in the nanomolar range ( 5-14 nm ) were recorded for the best representative . from time-dependent preincubation and rapid dilution study , and from docking analysis in a homology model of the target enzyme , a reversible mechanism of inhibition of hfaah is proposed .\", 'Label': -1}\n",
      "{'Verbatim': 'Title: inhibition of [ 3h ] pcck-8 binding to cholecystokinin type a receptor of rat pancreas\\n\\nDescription: title : 5- ( tryptophyl ) amino-1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine-based potent and selective cck ( 1 ) receptor antagonist : structure-activity relationship study on the central 1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine scaffold . abstract : to further define the pharmacophore of the potent and selective 5- ( tryptophyl ) amino-1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine-based cck ( 1 ) receptor antagonist the electronic and topographic property of the central 1,3-dioxoperhydro-pyrido [ 1,2-c ] pyrimidine scaffold have been modified . with this aim , the 1- and 3-oxo group have been replaced by the thioxo- and deoxi-analogues , and the fused piperidine ring ha been contracted to the corresponding pyrrolidine moiety . the result of the evaluation of the new analogue a cck receptor ligand , in rat pancreas and cerebral cortex preparation , showed that , whereas replacement of oxygen with sulfur is allowed , reduction of the 1- or 3-oxo group or the contraction of the fused piperidine ring lead to the complete loss of binding affinity at cck ( 1 ) receptor . the thioxo-analogues 5a , 8a , 12a , and 12b showed functional cck ( 1 ) antagonist activity , inhibiting the cck-8-stimulated amylase release from pancreatic acinar cell . the 1-thioxo analogue 5a , with subnanomolar affinity ( ic ( 50 ) = 0.09 x 10 ( -9 ) m ) , wa found to be the most potent and selective compound within the family of 5- ( tryptophyl ) amino-1,3-dioxoperhydropyrido [ 1,2-c ] pyrimidine-based cck ( 1 ) antagonist .', 'Label': None}\n",
      "{'Verbatim': 'Title: inhibition of hdac6 ( unknown origin )\\n\\nDescription: title : development of a selective hdac inhibitor aimed at reactivating the hiv latent reservoir . abstract : the synthesis and sar development of a trisubstituted imidazole hdac inhibitor is described . the compound were synthesized with high diastereocontrol by leveraging ellman sulfinyl imine chemistry . structural elucidation provided insight into binding mode and supported design rational . pharmacokinetic property of lead compound were determined .', 'Label': None}\n"
     ]
    }
   ],
   "source": [
    "# Define column descriptions\n",
    "column_descriptions = {\n",
    "    \"Title\": \"the title of the bioassay\",\n",
    "    \"Description\": \"the description of the bioassay\"\n",
    "}\n",
    "\n",
    "# Define instructions for multiclass classification\n",
    "# Instead of a dictionary of multiple themes, we have a single classification scenario\n",
    "theme_name = \"Phenotype Classification\"\n",
    "theme_description = \"\"\"\n",
    "The data consists of PubChem bioassays that measure compound activities on proteins.\n",
    "You must classify the bioassay phenotype into one of the following categories:\n",
    "- 1: activation (if the bioassay measures the activation of a protein),\n",
    "- -1: inhibition (if the bioassay measures the inhibition of a protein),\n",
    "- 0: unclassified (if the activity measured is not clear, or if the bioassay measures both activation and inhibition at the same time).\n",
    "\n",
    "The phenotype may not be clear in the title alone; please look into the description column to confirm the phenotype.\n",
    "\"\"\"\n",
    "\n",
    "data_format_description = build_data_format_description(column_descriptions)\n",
    "\n",
    "# Classification settings\n",
    "reasoning = False  # If True, perform two-step reasoning. If False, single-step classification.\n",
    "\n",
    "# Define queries for multiclass classification and reasoning\n",
    "multiclass_query = \"Reply with '1' for activation, '-1' for inhibition, or '0' for unclassified.\"\n",
    "reasoning_query = \"Generate a one-sentence reasoning about the classification (do not give the classification label)\"\n",
    "\n",
    "# Select subset of verbatims for testing\n",
    "verbatims_subset = verbatims[:15]\n",
    "\n",
    "def construct_prompt(verbatim, theme, theme_description):\n",
    "    \"\"\"\n",
    "    Constructs the base prompt for the given verbatim and the multiclass classification scenario.\n",
    "    \"\"\"\n",
    "    prompt = f\"\"\"\n",
    "You are a helpful assistant tasked with evaluating the following entry.\n",
    "\n",
    "You are provided with data entries in the following format:\n",
    "\n",
    "{data_format_description}\n",
    "\n",
    "**Entry:**\n",
    "{verbatim}\n",
    "\n",
    "**Task:**\n",
    "{theme} - {theme_description}\n",
    "\"\"\"\n",
    "    return prompt.strip()\n",
    "\n",
    "def generate_with_reasoning(llm_client, model_name, base_prompt, reasoning=False, temperature=0.0001, verbose=False):\n",
    "    \"\"\"\n",
    "    Generates a classification result for multiclass classification.\n",
    "\n",
    "    If reasoning is False, make one API call:\n",
    "        Base prompt + multiclass query directly.\n",
    "\n",
    "    If reasoning is True, make two API calls:\n",
    "        1) Base prompt + reasoning query (no classification yet).\n",
    "        2) Base prompt + reasoning answer_from_first_call + multiclass query.\n",
    "    \"\"\"\n",
    "    if reasoning:\n",
    "        # First call: get reasoning\n",
    "        first_prompt = f\"{base_prompt}\\n\\n{reasoning_query}\"\n",
    "        print(\"=== First LLM Prompt (Reasoning) ===\")\n",
    "\n",
    "        response_text_1, usage_1 = llm_client.get_response(\n",
    "            prompt=first_prompt,\n",
    "            model=model_name,\n",
    "            max_tokens=500,\n",
    "            temperature=temperature,\n",
    "            verbose=True\n",
    "        )\n",
    "\n",
    "        print(\"\\n=== LLM Response (Reasoning) ===\")\n",
    "        print(response_text_1)\n",
    "\n",
    "        # Second call: use reasoning answer for classification\n",
    "        second_prompt = f\"{base_prompt}\\n\\nReasoning:\\n{response_text_1}\\n\\n{multiclass_query}\"\n",
    "\n",
    "        print(\"\\n=== Second LLM Prompt (Classification) ===\")\n",
    "\n",
    "        response_text_2, usage_2 = llm_client.get_response(\n",
    "            prompt=second_prompt,\n",
    "            model=model_name,\n",
    "            max_tokens=500,\n",
    "            temperature=temperature,\n",
    "            verbose=True\n",
    "        )\n",
    "\n",
    "        if verbose:\n",
    "            print(\"\\n=== LLM Response (Classification) ===\")\n",
    "            print(response_text_2)\n",
    "\n",
    "        # Combine usage stats\n",
    "        usage_1.prompt_tokens += usage_2.prompt_tokens\n",
    "        usage_1.completion_tokens += usage_2.completion_tokens\n",
    "        usage_1.total_tokens += usage_2.total_tokens\n",
    "\n",
    "        return response_text_2, usage_1\n",
    "\n",
    "    else:\n",
    "        # Single-step classification: base prompt + multiclass query\n",
    "        single_prompt = base_prompt\n",
    "\n",
    "        print(\"=== Single-step Classification Prompt ===\")\n",
    "\n",
    "        response_text, usage = llm_client.get_response(\n",
    "            prompt=single_prompt,\n",
    "            model=model_name,\n",
    "            max_tokens=500,\n",
    "            temperature=temperature,\n",
    "            verbose=True\n",
    "        )\n",
    "        \n",
    "        print(\"\\n=== LLM Response (Single-step Classification) ===\")\n",
    "        print(response_text)\n",
    "\n",
    "        return response_text, usage\n",
    "\n",
    "# Initialize results and cost tracking\n",
    "results = []\n",
    "verbatim_costs = []\n",
    "total_tokens_used = 0\n",
    "total_cost = 0\n",
    "\n",
    "for idx, verbatim in enumerate(verbatims_subset):\n",
    "    print(f\"\\n=== Processing Verbatim {idx + 1}/{len(verbatims_subset)} ===\")\n",
    "    verbatim_tokens_used = 0\n",
    "    verbatim_cost = 0\n",
    "\n",
    "    print(f\"\\n--- Evaluating Theme: {theme_name} ---\")\n",
    "\n",
    "    # Build the base prompt\n",
    "    base_prompt = construct_prompt(\n",
    "        verbatim=verbatim, \n",
    "        theme=theme_name, \n",
    "        theme_description=theme_description\n",
    "    )\n",
    "\n",
    "    try:\n",
    "        response_content, usage = generate_with_reasoning(\n",
    "            llm_client=llm_client,\n",
    "            model_name=model_name,\n",
    "            base_prompt=base_prompt,\n",
    "            reasoning=reasoning,\n",
    "            temperature=0.0001,\n",
    "            verbose=True\n",
    "        )\n",
    "\n",
    "        # Track token usage\n",
    "        if usage:\n",
    "            prompt_tokens = usage.prompt_tokens\n",
    "            completion_tokens = usage.completion_tokens\n",
    "            total_tokens = usage.total_tokens\n",
    "\n",
    "            # Calculate the cost for this request\n",
    "            cost = openai_api_calculate_cost(usage, model=model_name)\n",
    "            total_tokens_used += total_tokens\n",
    "            total_cost += cost\n",
    "            verbatim_tokens_used += total_tokens\n",
    "            verbatim_cost += cost\n",
    "\n",
    "            # Print detailed token usage and cost\n",
    "            print(f\"\\nTokens Used: {prompt_tokens} (prompt) + {completion_tokens} (completion) = {total_tokens} total\")\n",
    "            print(f\"Cost for '{theme_name}': ${cost:.4f}\")\n",
    "\n",
    "        # Parse response\n",
    "        # This function should parse the returned text and extract the numerical label (1, 0, or -1)\n",
    "        # Make sure your `extract_code_from_response` can handle these values.\n",
    "        score = extract_code_from_response(response_content)\n",
    "        if score in [1, 0, -1]:\n",
    "            results.append({\n",
    "                'Verbatim': verbatim,\n",
    "                'Label': score\n",
    "            })\n",
    "            print(f\"Extracted Label: {score}\")\n",
    "        else:\n",
    "            print(\"Failed to parse a valid label.\")\n",
    "            results.append({\n",
    "                'Verbatim': verbatim,\n",
    "                'Label': None\n",
    "            })\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"Error processing Verbatim {idx + 1} for '{theme_name}': {e}\")\n",
    "        results.append({\n",
    "            'Verbatim': verbatim,\n",
    "            'Label': None\n",
    "        })\n",
    "\n",
    "    # Store verbatim-level cost\n",
    "    verbatim_costs.append({'Verbatim': verbatim, 'Tokens Used': verbatim_tokens_used, 'Cost': verbatim_cost})\n",
    "\n",
    "# Final Summary\n",
    "print(\"\\n=== Processing Complete ===\")\n",
    "print(f\"Total Tokens Used: {total_tokens_used}\")\n",
    "print(f\"Total Cost for Processing: ${total_cost:.4f}\")\n",
    "\n",
    "# Print final multiclass results\n",
    "for result in results:\n",
    "    print(result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Results saved to: data\\outputs\\experiment_gpt-4o_20241220_135630.csv\n"
     ]
    }
   ],
   "source": [
    "# Convert results to DataFrame\n",
    "results_df = pd.DataFrame(results)\n",
    "\n",
    "# Define the save path\n",
    "outputs_dir = os.path.join(data_dir, 'outputs')\n",
    "os.makedirs(outputs_dir, exist_ok=True)\n",
    "timestamp = datetime.now().strftime('%Y%m%d_%H%M%S')\n",
    "save_path = os.path.join(outputs_dir, f\"experiment_{model_name.replace('/', '_')}_{timestamp}.csv\")\n",
    "\n",
    "# Save results\n",
    "save_results_to_csv(\n",
    "    coding=results_df.to_dict('records'),\n",
    "    save_path=save_path,\n",
    "    fieldnames=['Verbatim', 'Label'],\n",
    "    verbatims=None  # Verbatims are included in the results\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Results loaded from: data\\outputs\\experiment_gpt-4o_20241220_135630.csv\n"
     ]
    }
   ],
   "source": [
    "# Load results\n",
    "loaded_results = load_results_from_csv(save_path)\n",
    "# The function returns (verbatims, coding)\n",
    "verbatims_loaded, coding_loaded = loaded_results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cohen's Kappa Score between human annotations and model: 0.00\n"
     ]
    }
   ],
   "source": [
    "# Assuming you have human annotations in the data\n",
    "human_annotations = data['y_true'].tolist()\n",
    "human_annotations = [int(x) for x in human_annotations]\n",
    "model_coding = results_df['Label'].tolist()\n",
    "model_coding = [int(x) for x in model_coding]\n",
    "\n",
    "human_annotations_short = human_annotations[:15]\n",
    "\n",
    "# Compute Cohen's Kappa\n",
    "kappa = compute_cohens_kappa(\n",
    "    human_annotations_short,\n",
    "    model_coding,\n",
    "    labels=[-1, 0, 1],\n",
    "    weights='linear'\n",
    ")\n",
    "\n",
    "print(f\"Cohen's Kappa Score between human annotations and model: {kappa:.2f}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Confusion Matrix\n",
    "cm = confusion_matrix(human_annotations_short, model_coding, labels=[-1, 0, 1])\n",
    "disp = ConfusionMatrixDisplay(confusion_matrix=cm, display_labels=[-1, 0, 1])\n",
    "disp.plot()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "gpt_rl",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
